Project description
Safeguarding cells in cell-based therapies
Over the years, various cell-based therapies have been developed against a wide range of diseases, including genetic disorders and cancer. Despite their preclinical promise, cell-based therapies suffer from low engraftment and retention of injected cells. To address this shortcoming, scientists of the EU-funded NOAHs-ARK project propose an encapsulation technology that safeguards cells against immune attack and supports their function. The technology consists of a chemically defined template enriched with various novel molecules suitable for specific therapeutic applications. Following in vitro validation, the technology will obtain regulatory approval before being commercialised for clinical application.
Objective
Cell and gene therapies holds tremendous therapeutic promise for patients worldwide and represent a valuable global market opportunity. Still, cell-based therapies present challenges related chiefly to cell retention, engraftment and survival. Minimally invasive cell delivery and improved retention by means of an encapsulation technology is a driver for generating more predictable clinical outcomes with lesser immune rejection in a variety of disease areas. Stemmatters has built a highly versatile platform technology to design novel molecules with attributes to safeguard cells and support cell function and retention. Based on a chemically defined template, our technology provides rapid generation of compound libraries supporting establishment of safe, less costly and more effective cell-based therapies. The performance and cost effectiveness of our development platform surpasses competing technologies.
NOAHs-ARK (spelled as Noah´s ark) aims to disrupt the current market landscape by developing Stemmatters’ encapsulation platform to other therapeutic applications of large unmet demand. Recruitment and integration of an Innovation associate (IA) with specific expertise in cell-based therapy into Stemmatters is a significant milestone that will dramatically increase Stemmatters capabilities, strengthen existing collaborations, and expand business opportunities. The IA will provide Stemmatters with important technical expertise and a comprehensive understanding of market unmet needs and current competitive dynamics. The IA will lead development of our innovative platform to other therapeutic applications of large unmet need, by designing in vitro studies for specific disease indications in need of enabling cell encapsulation solutions. Biomaterials entering the pipeline will be supported by technical product dossiers to assist regulatory submissions, smooth translation to the clinic and commercialization by strategic licensing and/or supply agreements.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- engineering and technology industrial biotechnology biomaterials
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.2.2. - Enhancing the innovation capacity of SMEs
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
CSA - Coordination and support action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-INNOSUP-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
4805-017 Barco Gmr
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.